Comparative performance of Cobas 4800 and 5800 assays with Cobas 6800 assay for detecting/genotyping high-risk HPV in cervical samples: An interlaboratory evaluation in Maputo, Mozambique
African Journal of Clinical and Experimental Microbiology · 2026 · 27 (2) · 151-159
DOI: 10.4314/ajcem.v27i2.4 ↗Kurz gefasst
Fachartikel in der Zeitschrift African Journal of Clinical and Experimental Microbiology, 2026. Verfasst von A. Sineque und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Background
High-risk (hr) human papillomaviruses (HPV) testing is immensely important in elucidating molecular epidemiology of HPV infections and has become an essential part of current clinical practice in the management of the precancerous lesions and cervical cancer risks. Evaluation of HPV testing systems suitable for large-scale organized cervical screening programs is required. Very little is known about the diagnostic performance of the Cobas assays in resource-limited settings, particularly in Mozambique. We evaluated the concordance of the Cobas 4800 and Cobas 5800 assays with the Cobas 6800 assay for detecting high-risk HPV genotypes in clinician-collected cervical samples.Methodology: In Mozambique, HPV-based cervical cancer screening is being regionally implemented and is currently well established in Maputo using the Cobas 4800, Cobas 5800 and Cobas 6800 assays. A random subset of 124 samples from women older than 18 years attending organized cervical cancer screening and previously tested for hrHPV-DNA using Cobas 4800 and Cobas 5800, were used for a subsequent analysis on Cobas 6800.
Results
Our results showed a good-to-high overall concordance of the Cobas 4800 and Cobas 5800 tests with Cobas 6800 test, showing strong Cohen’s kappa values (95%, κ=0.89, 95% CI: 0.80–0.98, for Cobas 4800 versus Cobas 6800; and 100%, κ=1.00, 95% CI: 1.00–1.00 for Cobas 5800 versus Cobas 6800). Similar performance to detect HPV-16, HPV-18, and the 12 other hrHPV genotypes was observed.
Conclusion
The global performance to detect the 14 hrHPV genotypes was not significantly different between the three Cobas assays, which supports their suitability for use in large centralized laboratories included within population-based cervical cancer screening programs in resource-limited settings.
Zitieren
APA
Sineque, A., Condo, T., Sebastião, J., Nhambe, C., Manuel, M., Mabasso, A., Sidumo, Z., Ceffa, S., & Ciccacci, F. (2026). Comparative performance of Cobas 4800 and 5800 assays with Cobas 6800 assay for detecting/genotyping high-risk HPV in cervical samples: An interlaboratory evaluation in Maputo, Mozambique. African Journal of Clinical and Experimental Microbiology, 27(2), 151-159. https://doi.org/10.4314/ajcem.v27i2.4
Vancouver
Sineque A, Condo T, Sebastião J, Nhambe C, Manuel M, Mabasso A, et al. Comparative performance of Cobas 4800 and 5800 assays with Cobas 6800 assay for detecting/genotyping high-risk HPV in cervical samples: An interlaboratory evaluation in Maputo, Mozambique. African Journal of Clinical and Experimental Microbiology. 2026;27(2):151-159. doi:10.4314/ajcem.v27i2.4
BibTeX
@article{Sineque2026,
author = {Sineque, A. and Condo, T. and Sebastião, J. and Nhambe, C. and Manuel, M. and Mabasso, A. and Sidumo, Z. and Ceffa, S. and Ciccacci, F.},
title = {Comparative performance of Cobas 4800 and 5800 assays with Cobas 6800 assay for detecting/genotyping high-risk HPV in cervical samples: An interlaboratory evaluation in Maputo, Mozambique},
journal = {African Journal of Clinical and Experimental Microbiology},
year = {2026},
volume = {27},
number = {2},
pages = {151--159},
doi = {10.4314/ajcem.v27i2.4}
}
EUVIMED